Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Acquired Immunodeficiency Syndrome (AIDS) Market Growth Evolved From 2024 To 2025, And What’s Ahead?
Strong growth has been observed lately in the acquired immunodeficiency syndrome (aids) market. The market, valued at $32.09 billion in 2024, is projected to further increase to $33.75 billion in 2025 with a compound annual growth rate (CAGR) of 5.2%. Factors such as a hike in HIV infection rates, augmented government funding towards HIV treatment, proliferation of worldwide awareness programs, enhancement in diagnostic facilities, and increased aid from non-governmental organizations have contributed to the notable growth in the past.
The market for acquired immunodeficiency syndrome (aids) is projected to experience robust expansion in the imminent years. The market is anticipated to escalate to$41.28 billion in 2029, charting a compound annual growth rate (CAGR) of 5.2%. The augmentation in the stipulated period is credited to the escalating requirements for durable injectable treatments, the burgeoning adoption of pre-exposure prophylaxis (PrEP), elevated funding in HIV remedy investigations, the proliferation of telemedicine provisions for HIV care, heightened emphasis on personalized medication, and burgeoning cognizance about early HIV diagnosis. Predominant tendencies forecasted for this period comprise a shift towards single-tablet routines, a rising predilection for injectable and implantable HIV therapies, accelerated demand for digital health solutions in HIV administration, developing curiosity in functional HIV cure strategies, and the enlarging influence of artificial intelligence in drug discovery.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp
What Are the Core Market Drivers Propelling Growth in the Acquired Immunodeficiency Syndrome (AIDS) Industry?
The escalation in HIV infection rates is projected to fuel the expansion of the acquired immunodeficiency syndrome (AIDS) market. HIV infections are conditions instigated by the human immunodeficiency virus (HIV), a virus that weakens and attacks the immune system, limiting its ability to combat infections and diseases. The uptick in HIV infection rates can be attributed to unsafe sexual practices with an infected partner, using shared needles or syringes, exposure to contaminated blood products, engaging in sexual activities with multiple partners, and a compromised immune or sexually transmitted infections. Management strategies for AIDS play a crucial role in assisting HIV-infected patients by encouraging early detection, increasing access to potent antiretroviral therapies, improving prevention methods, and reinforcing healthcare systems that help manage the viral spread effectively. For example, in November 2024, data released by the Sweden-based European Centre for Disease Prevention and Control (ECDC) indicated that 112,883 HIV diagnoses were made in 2023 across 47 of the 53 countries in the region, with 24,731 instances identified in the European Union/European Economic Area (EU/EEA). The total crude HIV diagnosis rate stood at 12.7 per 100,000 population, marking a 2.4% surge compared to the 12.4 per 100,000 rates detected in 2022. Thus, the rise in HIV infections constitutes a significant driver for the AIDS market.
How Is the Acquired Immunodeficiency Syndrome (AIDS) Market Segmented?
The acquired immunodeficiency syndrome (aids)market covered in this report is segmented –
1) By Type: Human Immunodeficiency Virus 1; Human Immunodeficiency Virus 2
2) By Drug Type: Nucleoside-Analog Reverse Transcriptase Inhibitors; Non-Nucleoside Reverse Transcriptase Inhibitors; Fusion Inhibitors; CCR5 Anatagonists And Post-Attachment Inhibitors; Protease Inhibitors; Integrase Inhibitors; Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis
3) By Route Of Administration: Oral; Parenteral
4) By Application: Hospital Pharmacy; Retail Pharmacy; Other Applications
5) By Distribution Channel: Offline; Online
Subsegments:
1) By Human Immunodeficiency Virus 1 (HIV-1): Antiretroviral Therapy (ART); Pre-Exposure Prophylaxis (PrEP); Post-Exposure Prophylaxis (PEP); HIV-1 Diagnostic Tests; HIV-1 Vaccine Development; HIV-1 Opportunistic Infection Management
2) By Human Immunodeficiency Virus 2 (HIV-2): Antiretroviral Therapy (ART) For HIV-2; HIV-2 Diagnostic Tests; HIV-2 Surveillance And Epidemiology; HIV-2 Vaccine Research; Management Of HIV-2 Co-Infections
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21076&type=smp
Which Regions Are Driving the Next Phase of the Acquired Immunodeficiency Syndrome (AIDS) Market Growth?
North America was the largest region in the acquired immunodeficiency syndrome (AIDS) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired immunodeficiency syndrome (AIDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Key Market Trends and Innovations Are Shaping the Future of the Acquired Immunodeficiency Syndrome (AIDS) Industry?
Leading firms in the acquired immunodeficiency syndrome (AIDS) market are putting their efforts into bringing forth groundbreaking treatments such as long-acting injectables. These injectables can enhance patient adherence, diminish the regularity of dosage, and present a more agreeable alternative to daily oral antiretroviral therapies. Long-acting injectables, medications dispensed through injection, are purposed to gradually release active components over a longer duration, thereby demanding less frequent administration than standard oral drugs. To illustrate, in January 2025, GSK plc., a pharmaceutical corporation based in the UK, received approval from the European Commission for its long-acting injectable treatment, Vocabria (cabotegravir) and Rekambys (rilpivirine). This treatment is authorised for adolescents 12 years or older living with HIV and is administered through an intramuscular injection, typically once or twice a month, based on the individual treatment strategy. The long-acting characteristic of these injections may enhance compliance rates among teenagers who find daily pill routines problematic.
View the full report here:
How Is the Acquired Immunodeficiency Syndrome (AIDS) Market Defined and What Are Its Core Parameters?
Acquired immunodeficiency syndrome (AIDS) is a chronic, life-threatening condition caused by the human immunodeficiency virus (HIV), which progressively weakens the immune system by destroying CD4 T cells, leaving the body vulnerable to opportunistic infections, severe illnesses, and certain cancers in the absence of effective antiretroviral treatment. It is managed by a combination of antiretroviral therapy (ART), regular monitoring of immune function, prevention of opportunistic infections, and comprehensive healthcare support to improve patient outcomes and quality of life.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21076
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
